论文部分内容阅读
目的:观察低分子肝素钠联合尼莫地平治疗进展性脑梗死的临床疗效。方法:选取我科收治的进展性脑梗死患者82例,随机分为试验组和对照组,每组41例。对照组给予血栓通静滴,每日一次。试验组给予低分子肝素钠脐周皮下注射,Q12 h,尼莫地平静脉滴注,每日两次。对治疗前和治疗3 d、7 d和14 d后患者的凝血功能及临床神经功能缺损评分进行评定,比较评估两组患者治疗14 d后临床疗效。结果:试验组和对照组治疗3 d、7 d和14 d后NIHSS评分较治疗前均降低(P<0.05)。试验组总有效率显著优于对照组(90.2%vs 70.7%,P<0.05)。结论:低分子肝素联合尼莫地平能够有效改善进展性脑梗死患者的神经功能及预后,且具有较高安全性,值得临床推广使用。
Objective: To observe the clinical efficacy of low molecular weight heparin combined with nimodipine in the treatment of patients with progressive cerebral infarction. Methods: Selected 82 patients with progressive cerebral infarction admitted to our department, were randomly divided into experimental group and control group, 41 cases in each group. Control group given intravenous thrombus, once daily. Experimental group given low molecular weight heparin umbilical subcutaneous injection, Q12 h, nimodipine intravenous infusion, twice daily. The coagulation function and clinical neurological deficit scores of patients before treatment, 3 d, 7 d and 14 d after treatment were evaluated. The clinical efficacy of the two groups after 14 days of treatment was compared and evaluated. Results: The NIHSS scores of experimental group and control group after 3 d, 7 d and 14 d were lower than those before treatment (P <0.05). The total effective rate of the experimental group was significantly better than that of the control group (90.2% vs 70.7%, P <0.05). Conclusion: Low molecular weight heparin combined with nimodipine can effectively improve the neurological function and prognosis of patients with progressive cerebral infarction, and has high safety and is worthy of clinical promotion.